UCB is beefing up its gene therapy ops with back-to-back deals to buy a startup and sign up a university spinout for discovery work
Belgian pharma player UCB is adding AAV gene therapy programs to the R&D menu through a pair of deals struck in Europe and the US …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
